For my penultimate Barchart article in 2025, I wanted to revisit Indivior (INDV), a Virginia-based developer of opioid addiction treatments that I last covered in early September. At the time, INDV stock had just moved up 11 spots into the top 50 on Barchart’s Top 100 Stocks to Buy list. On Monday, the stock rose 12 spots to 38th, eight places higher than in early fall. More News from Barchart In the past 364 days, Indivior’s share price has risen nearly 200%, with 47% of the gains in the three-plus m ...